Venlafaxine Hydrochloride interactions

Checked as Venlafaxine in this data source.

Full monograph for Venlafaxine Hydrochloride Check it against another medicine

Medicines

724 documented

Severity

Mechanism

Medicines documented to interact with Venlafaxine Hydrochloride, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Almotriptan	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Amiodarone Hydrochloride	Major	Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…	45 sources — open the full entry
Amisulpride	Major	Synergy	Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the…	3 sources — open the full entry
Amitriptyline Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Amitriptyline Hydrochloride + Chlordiazepoxide	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	144 sources — open the full entry
Arsenic Trioxide	Major	Synergy	Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the…	4 sources — open the full entry
Artemether + Lumefantrine	Major	Synergy	Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms	16 sources — open the full entry
Bupropion Hydrochloride	Major	Synergy	The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin…	19 sources — open the full entry
Cabozantinib	Major	Synergy	Cabozantinib can cause prolongation of the QT interval.	7 sources — open the full entry
Ceritinib	Major	Synergy	Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval…	9 sources — open the full entry
Chloroquine Phosphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Citalopram Hydrobromide	Major	Synergy	Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval…	22 sources — open the full entry
Clomipramine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Clozapine	Major	Synergy	Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation…	13 sources — open the full entry
Crizotinib	Major	Synergy	Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT…	6 sources — open the full entry
Cyclobenzaprine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Desvenlafaxine Succinate	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Dextromethorphan + Bupropion	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	153 sources — open the full entry
Dextromethorphan + Phenylephrine + Triprolidine	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…3 documented mechanisms	190 sources — open the full entry
Dextromethorphan + Pseudoephedrine + Triprolidine	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…3 documented mechanisms	190 sources — open the full entry
Dextromethorphan Hydrobromide	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Dextromethorphan Hydrobromide + Guaifenesin	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Dextromethorphan Polistirex	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Diphenhydramine + Dextromethorphan + Levomenthol	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	178 sources — open the full entry
Doxepin (Oral)	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Doxepin (Topical)	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Duloxetine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Efavirenz	Major	Metabolism	Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 6/6 genotype due to reduced metabolic clearance of the drug stemming…	6 sources — open the full entry
Escitalopram Oxalate	Major	Synergy	Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants…	39 sources — open the full entry
Fentanyl Citrate	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Fluoxetine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Fluphenazine + Nortriptyline	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	102 sources — open the full entry
Fluvoxamine Maleate	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Gatifloxacin	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Gatifloxacin + Dexamethasone	Major	Synergy · Unknown	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms	28 sources — open the full entry
Granisetron	Major	Synergy	Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as antidepressants and lithium may potentiate the…	7 sources — open the full entry
Guaifenesin + Dextromethorphan + Menthol	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Haloperidol	Major	Synergy	Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as…	15 sources — open the full entry
Hydroxychloroquine Sulphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Iloperidone	Major	Synergy	Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	9 sources — open the full entry
Imipramine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Iohexol	Major	Synergy	Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of…	5 sources — open the full entry
Iopamidol	Major	Synergy	Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of…	5 sources — open the full entry
Ivabradine	Major	Synergy	Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong…	10 sources — open the full entry
Ivosidenib	Major	Synergy	Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive…	6 sources — open the full entry
Lasmiditan Hemisuccinate	Major	Synergy	Coadministration of lasmiditan and serotonergic agents may increase the risk of serotonin syndrome. Lasmiditan binds to the 5-HT(1F) receptor, where it…	5 sources — open the full entry
Lefamulin Acetate	Major	Synergy	Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result…	6 sources — open the full entry
Levomilnacipran Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Linezolid	Major	Synergy	Coadministration of linezolid with serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal…	52 sources — open the full entry
Lithium Carbonate	Major	Synergy	Lithium may enhance the pharmacologic effects of serotonin reuptake inhibitors (e.g., SSRIs, SNRIs, nefazodone, trazodone) and potentiate the risk of serotonin…	22 sources — open the full entry

Food & lifestyle

alcohol
Moderate
Synergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
4 sources
1. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
2. Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
3. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
4. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):

Conditions

Conditions in which Venlafaxine Hydrochloride needs care, as documented in this source.

Depressive Disorder
Major
Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Kidney Diseases
Major
The clearance of SNRI antidepressants is decreased in subjects with renal impairment. SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment. The use of SNRIs is not recommended in patients with end-stage renal disease.
4 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
3. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
4. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Liver Diseases
Major
Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney. Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance. Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function. A reduction in the total daily dosage is recommended. The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).
2 sources
1. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST "Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite." J Clin Pharmacol 32 (1992): 716-24
2. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
Glaucoma
Moderate
SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Hypertension
Moderate
Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure. Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension. Blood pressure should be assessed prior to initiating treatment and monitored regularly. The dose should be reduced or discontinued if necessary.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Hyponatremia
Moderate
Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Mania
Moderate
All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.
18 sources
1. Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988): 804-8
2. Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991): 233-6
3. Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
4. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
5. Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984): 1103-4
6. Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986): 1482-3
7. Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987): 423-4
8. Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991): 275-8
Show all 18 sourcesShow fewer sources
1. Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987): 274-5
2. Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986): 787-9
3. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
4. Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993): s45-50
5. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
6. Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995): 218
7. "Product Information. Remeron (mirtazapine)." Organon (2001):
8. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
9. Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997): 578-9
10. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):
Seizures
Moderate
SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Urethral Obstruction
Moderate
SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.
5 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company (2004):
3. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories (2008):
4. "Product Information. Savella (milnacipran)." Forest Pharmaceuticals (2009):
5. "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals (2013):
Weight Loss
Minor
The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo. Anorexia may occur in approximately 10% of patients. Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.
2 sources
1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
2. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994): 99-106

Therapeutic duplication

Drug classes that overlap with Venlafaxine Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/dextromethorphan
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Fluoxetine/olanzapine
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Limbitrol ds
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/naltrexone
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Amitriptyline/perphenazine

Medicines

Food & lifestyle

alcohol

Conditions

Depressive Disorder

Kidney Diseases

Liver Diseases

Glaucoma

Hypertension

Hyponatremia

Mania

Seizures

Urethral Obstruction

Weight Loss

Therapeutic duplication

antidepressants

antidepressants

antidepressants

antidepressants

antidepressants